A Phase I Study of Oxaliplatin in Combination With Capecitabine in Metastatic/Recurrent Solid Tumors

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or recurrent
solid tumor that has failed standard therapy or for which no standard therapy exists No
known brain metastases or carcinomatosis meningitis

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Karnofsky 60-100%
Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute
neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin
no greater than 2 times normal AST no greater than 2.5 times normal Renal: Creatinine
normal OR Creatinine clearance greater than 60 mL/min Calcium no greater than 12 mg/dL
Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No
cardiac arrhythmia Other: No evidence of neuropathy No history of allergies to platinum
compounds or antiemetics that would preclude study No other uncontrolled illness (e.g.,
ongoing or active infection) No medical, social, or psychological factors that would
preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use
effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and
recovered Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin
and nitrosoureas) and recovered Prior fluorouracil or cisplatin allowed Endocrine therapy:
Not specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered
Surgery: Recovered from prior surgery Other: At least 30 days since prior investigational
drugs No concurrent antiretroviral therapy (HAART)